LACK OF ASSOCIATION BETWEEN VARIANTS WITHIN THE
AHSG, HCRT AND NPY2R GENES AND ANTHROPOMETRICAL
PARAMETERS IN CZECH POST-MONICA STUDY Jurcikova L*, Adamkova V, Lanska V, Suchanek P, Hubacek JA *Corresponding Author: Ing. Lucie Jurčíková, Institute for Clinical and Experimental Medicine, DEM, Videnska
1958/9, Prague 4, 14021, Czech Republic; Tel.: +420-261-362-229; Fax: +420-241-721-574; E-mail: jurl@ikem.cz page: 63
|
REFERENCES
1. Lavebratt C, Alpman A, Persson B, Arner P, Hoffstedt
J. Common neuropeptide Y2 receptor gene
variant is protective against obesity among Swedish
men. Int J Obes. 2006; 30(3): 453-459.
2. Suchanek P, Kralova-Lesna I, Pledne R, Lanska
V, Hubacek JA. An AHSG gene variant modulates
baal metabolic rate and body composition
development after a short-time lifestyle intervention.
Neuroendocrinol Lett. 2011; 32(suppl 2):
32-36.
3. Dahlman I, Eriksson P, Kaaman M, Jiao H, Lindgren
CM, Kere J, et al. a2-Heremans-Schmid
glycoprotein gene polymorphisms are associated
with adipocyte insulin action. Diabetologia.
2004; 47(11): 1974-1979.
4. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson
F. A synonymous coding polymorphism in
the a2-Here-mans-schmid glycoprotein gene is
associated with type 2 diabetes in French Caucasians.
Diabetes. 2005; 54(8): 2477-2481.
5. Stefan N, Hennige AM, Staiger H, Machann J,
Schick F, Kröber SM, et al. a2-Heremans-Schmid
glyco-protein/fetuin-A is associated with insulin
resistance and fat accumulation in the liver in
humans. Diabetes Care. 2006; 29(4): 853-857.
6. Fisher E, Stefan N, Saar K, Drogan D, Schulze
MB, Fritsche A, et al. Association of AHSG gene
polymor-phisms with fetuin-A plasma levels and
cardiovascular diseases in the EPIC-Potsdam
study. Circ Cardiovasc Genet. 2009; 2(6): 607-613.
7. Muendlein A, Stark N, Rein P, Saely CH, Geller-
Rhomberg S, Geiger K, et al. Are AHSG polymorphisms
directly associated with coronary
atherosclerosis? Clin Chim Acta. 2012; 413(1-2):
287-290.
8. Andersen G, Burgdorf KS, Sparsø T, Borch-
Johnsen K, Jørgensen T, Hansen T, et al. AHSG
tag single nucleotide polymorphisms associate
with type 2 diabetes and dyslipidemia: studies of
metabolic traits in 7,683 white Danish subjects.
Diabetes. 2008; 57(5): 1427-1432.
9. Mathews ST, Singh GP, Ranalletta M, Cintron
VJ, Qiang X, Goustin AS, et al. Improved insulin
sensitivity and resistance to weight gain in mice
null for the AHSG gene. Diabetes. 2002; 51(8):
2450-2458.
10. Ganjavi H, Shapiro CM. Hypocretin/Orexin: a
molecular link between sleep, energy regulation,
and pleasure. J Neuropsychiatry Clin Neurosci.
2007; 19(4): 413-419.
11. Sakurai T, Moriguchi T, Furuya K, Kajiwara N,
Nakamura T, Yanagisawa M, et al. Structure and
function of human prepro-orexin gene. J Biol
Chem. 1999; 274(25): 17771-17776.
12. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye
PE, Danielson PE, et al. The hypocretins: hypothalamus-
specific peptides with neuroexcitatory
activity. Proc Natl Acad Sci USA. 1998; 95(1):
322-327.
13. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli
RM, Tanaka H, et al. Orexins and orexin
receptors: a family of hypothalamic neuropeptides
and G protein-coupled receptors that regulate
feeding behavior. Cell. 1998; 92(4): 573-585.
14. Hara J, Beuckmann CT, Nambu T, Willie JT,
Chemelli RM, Sinton CM, et al. Genetic ablarton
of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuwron. 2001; 30(2):
345-354.
15. Bronsky J, Nedvidkova J, Zamrazilova H,
Pechova M, Chada M, Kotaska K, et al. Dynamic
changes of orexin A and leptin in obese children
during body weight reduction. Physiol Res. 2007;
56(1): 89-96.
16. Adam JA, Menheere PPCA, Van Dielen FMH,
Soeters PB, Buurman WA, Greve JWM. Decreased
plasma orexin-A levels in obese individuals.
Int J Obes Relat Metab Disord. 2002;
26(2): 274-276.
17. Kok SW, Meinders AE, Overeem S, Lammers
GJ, Roelfsema F, Frölich M, et al. Reduction
of plasma leptin levels and loss of its circadian
rhythmicity in hypocretin (orexin)-deficient narcoleptic
humans. J Clin Endocrinol Metab. 2002;
87(2): 805-809.
18. Hungs M, Lin L, Okun M, Mignot E. Polymorphisms
in the vicinity of the hypocretin/orexin are
not associated with human narcolepsy. Neurology.
2001; 57 (10): 1893-1895.
19. Ammar DA, Eadie DM, Wong DJ, Ma Y-Y,
Kolakowski LF Jr, Yang-Feng TL, et al. Characterization
of the human type 2 neuropeptide
Y receptor gene (NPY2R) and localization to
the chromosome 4q region containing the type 1
neuropeptide Y receptor gene. Genomics. 1996;
38(3): 392-398.
20. Chen C-H, Stephens RL Jr, Rogers RC. PYY and
NPY: control of gastric motility via action on Y1
and Y2 receptors in the DVC. Neurogastroenterol
Mot. 1997; 9(2): 109-116.
21. Siddiq A, Gueorguiev M, Samson C, Hercberg S,
Heude B, Levy-Marchal C, et al. Single nucleotide
polymorphisms in the neuropeptide Y2 receptor
(NPY2R) gene and association with severe
obesity in French white subjects. Diabetologia.
2007; 50(3): 574-584.
22. Hunt SC, Hasstedt SJ, Xin Y, Dalley BK, Malish
BA, Yakobson E, et al. Polymorphisms in
the NPY2R gene show significant associations
with BMI that are additive to FTO, MC4R, and
NPFFR2 gene effects. Obesity. 2011; 19(11):
2241-2247.
23. Hung Ch-ChC, Pirie F, Luan J, Lank E, Motala
A, Yeo GSH, et al. Studies of the peptide YY and
neuropep-tide Y2 receptor genes in relation to human
obesity and obesity-related traits. Diabetes.
2004; 53(9): 2461-2466.
24. Tunstall-Pedoe H. MONICA’s quarter century. Eur
J Cardiovasc Prev Rehabil. 2003; 10(6): 409-410.
25. Thunsdall-Pedoe H, Kuulasmaa K, Tolonen H,
Davidson M, Mendis S. MONICA monograph
and multimedia sourcebook. Thunsdall-Pedoe H,
Ed. Geneva: World Health Organization, 2003.
26. Ishibashi A, Ikeda Y, Ohguro T, Kumon Y, Yamanaka
S, Takata H, et al. Serum fetuin-A is an
independent marker of insulin resistance in Japanese
men. J Atheroscler Thromb. 2010; 17(9):
925-933.
27. Singh M, Sharma PK, Garg VK, Mondal SC,
Singh AK, Kumar N. Role of fetuin-A in atherosclerosis
associated with diabetic patients. J
Pharm Pharmacol. 2012; 64(12): 1703-1708.
|
|
|
|
|
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|